Focus Taiwan App

OBI Pharma announces COVID-19 vaccine clinical trials to start in 2022

02/08/2022 08:38 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taipei, Feb. 8 (CNA) Taiwan-based biotech firm OBI Pharma Inc. announced Tuesday that the COVID-19 vaccine it developed called BCVax will enter phase 1 & 2 clinical trials in the second half of this year.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.